Literature DB >> 22480994

Progress in the treatment of lymphangioleiomyomatosis: from bench to bedside.

A M Taveira-DaSilva1, J Moss.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22480994      PMCID： PMC4142050          DOI： 10.1016/j.rppneu.2012.02.005

Source DB:  PubMed          Journal:  Rev Port Pneumol        ISSN： 0873-2159


× No keyword cloud information.
  17 in total

1.  Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.

Authors:  Darcy A Krueger; Marguerite M Care; Katherine Holland; Karen Agricola; Cynthia Tudor; Prajakta Mangeshkar; Kimberly A Wilson; Anna Byars; Tarek Sahmoud; David Neal Franz
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

2.  Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis.

Authors:  T Carsillo; A Astrinidis; E P Henske
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

3.  Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone.

Authors:  Angelo M Taveira-DaSilva; Mario P Stylianou; Carolyn J Hedin; Olanda Hathaway; Joel Moss
Journal:  Chest       Date:  2004-12       Impact factor: 9.410

4.  Involvement of lymphatics in lymphangioleiomyomatosis.

Authors:  Connie G Glasgow; Angelo Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Katsuya Tsukada; Xiong Cai; Souheil El-Chemaly; Joel Moss
Journal:  Lymphat Res Biol       Date:  2009-12       Impact factor: 2.589

5.  Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.

Authors:  Angelo M Taveira-DaSilva; Olanda Hathaway; Mario Stylianou; Joel Moss
Journal:  Ann Intern Med       Date:  2011-06-21       Impact factor: 25.391

6.  Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.

Authors:  Heidi Kenerson; Trevor A Dundon; Raymond S Yeung
Journal:  Pediatr Res       Date:  2004-11-19       Impact factor: 3.756

7.  Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis.

Authors:  T A Smolarek; L L Wessner; F X McCormack; J C Mylet; A G Menon; E P Henske
Journal:  Am J Hum Genet       Date:  1998-04       Impact factor: 11.025

8.  Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment.

Authors:  Nisreen El-Hashemite; Hongbing Zhang; Victoria Walker; Karin M Hoffmeister; David J Kwiatkowski
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

9.  Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis.

Authors:  Toshiaki Ohara; Takahiro Oto; Kentaro Miyoshi; Hiroyuki Tao; Masaomi Yamane; Shinichi Toyooka; Megumi Okazaki; Hiroshi Date; Yoshifumi Sano
Journal:  Ann Thorac Surg       Date:  2008-12       Impact factor: 4.330

Review 10.  Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.

Authors:  Elena A Goncharova; Vera P Krymskaya
Journal:  J Cell Biochem       Date:  2008-02-01       Impact factor: 4.429
View more
  1 in total

1.  Lymphangioleiomyomatosis: current and future.

Authors:  Maria Mavroudi; Paul Zarogoulidis; Nikolaos Katsikogiannis; Kosmas Tsakiridis; Haidong Huang; Antonios Sakkas; Anastasios Kallianos; Aggeliki Rapti; Eirini Sarika; Ilias Karapantzos; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.